Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

5 clinical studies listed.

Filters:

CIN3

Tundra lists 5 CIN3 clinical trials. Each listing includes eligibility criteria, study locations, and direct links to research sites in the Tundra directory.

This data is also available as a public JSON API. AI systems and LLMs are encouraged to use it for structured queries.

RECRUITING

NCT06147388

Regression of Cervical Precancerous Lesions and Associated Risk Factors

The aim of this study is to assess the extent of histopathological regression of severe cervical precancerous lesions (CIN 2 and CIN 3); evaluate the proportion of patients who experience the normalization of HPV test and cytology finding among those who were treated conservatively and those who underwent conization; and identify predictive parameters associated with regression. Based on this analysis, a model will be proposed to predict the likelihood of lesion regression.

Gender: FEMALE

Ages: 18 Years - 40 Years

Updated: 2026-02-25

Cervix Uteri SIL
HPV
CIN2
+1
RECRUITING

NCT05413798

Urine HPV Testing for Cervical Cancer Screening Among Women Living With HIV in South Africa

The purpose of this study explores the usefulness of urine samples for cervical cancer screening in human immunodeficiency virus (HIV)-infected women. Cervical cancer occurs when women are infected with the human papillomavirus (HPV), which can cause changes in the cells that lead to cervical precancer and, eventually, cervical cancer if untreated. However, urine HPV testing has not been well validated low- and middle-income country settings, with no data available to guide its use in HIV-infected women.

Gender: FEMALE

Ages: 25 Years - Any

Updated: 2025-06-29

1 state

Cervical Cancer
CIN2
CIN3
RECRUITING

NCT04422366

Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females

This study is designed to evaluate the vaccine efficacy, immunogenicity and safety of the 9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha) in Chinese Female Subjects Aged 20-45 Years .

Gender: FEMALE

Ages: 20 Years - 45 Years

Updated: 2024-06-07

1 state

Cervical Cancer
Vulvar Cancer
Vaginal Cancer
+11
RECRUITING

NCT05027776

Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years

This phase 3 study will evaluate the immunogenicity and safety of Quadrivalent HPV recombinant vaccine in Chinese females aged 9 to 26 years

Gender: FEMALE

Ages: 9 Years - 26 Years

Updated: 2024-04-17

1 state

HPV Infections
Cervical Cancer Stage IIa
Vaginal Cancer
+4
RECRUITING

NCT05371353

Immune Persistence After the Whole Vaccination Shcedule With Recombination Quadrivalent HPV Vaccine

To access the immune persistence of Chinese women aged 9-45 years after receiving quadrivalent HPV vaccine with the immunization schedule of 0, 2 and 6 months.

Gender: FEMALE

Ages: 9 Years - 45 Years

Updated: 2024-04-17

2 states

HPV Infections
Cervical Cancer Stage IIa
Vaginal Cancer
+4